{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-22-000002","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.120181+00:00","generated_at":"2026-06-27T20:40:11.100494+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"low","headline":"Immunovant provides Phase 3 update for batoclimab in myasthenia gravis","bullets":["Corporate webcast held Jan 5, 2022; presentation focuses on Phase 3 development of batoclimab.","Batoclimab is the company's lead anti-FcRn antibody candidate for myasthenia gravis.","No specific clinical data or milestones were disclosed in the filing or attached presentation.","Update may include trial design, enrollment status, or regulatory timeline; details not provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-22-000002","json":"https://secwatch.observer/filing/0001764013-22-000002.json","markdown":"https://secwatch.observer/filing/0001764013-22-000002.md","text":"https://secwatch.observer/filing/0001764013-22-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000002/0001764013-22-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000002/imvt-20220105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:40:11.100494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}